Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.57 |
| ▸ | MAOA | P21397 | 7/20 | 0.57 |
| ▸ | PYCR1 | P32322 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20018096 | 1.00 | MAOB (0.57) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL17689237 | 1.00 | MAOB (0.57) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL2471455 | 1.00 | MAOB (0.57) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL17689247 | 0.84 | MAOB (0.46) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL694708 | 0.81 | MAOB (0.57) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL18079509 | 0.81 | MAOB (0.57) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL694707 | 0.81 | MAOB (0.57) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL2479514 | 0.81 | MAOB (0.57) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL13154527 | 0.77 | MAOB (0.68) | MAOBMAOAPYCR1TSHRLMNA | |
| SCHEMBL2477320 | 0.77 | MAOB (0.68) | MAOBMAOAPYCR1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101302-A1 | NOVEL PRECURSOR MOLECULES FOR F-18 LABELLED PET TRACERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20100233086-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20090191129-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | Lantheus Biosciences Ltd. (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101302-A1 | NOVEL PRECURSOR MOLECULES FOR F-18 LABELLED PET TRACERS | MPI, TMEM14C, FDPS | MAOB 683/4885MAOA 718/4885PYCR1 557/4885 |
| US-20090191129-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | MAOB 206/4885MAOA 788/4885PYCR1 1519/4885 |
| US-20100233086-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | MAOB 206/4885MAOA 788/4885PYCR1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.